## Editor's <br> Report <br> Volume 92, 2021

## Production

The 6 issues of volume 92, year 2021 (2020, 2019, 2018, 2017, 2016) contained 765 (803, $626,701,704,655)$ pages with $125(119,101$, $112,112,102)$ articles.

Of these, 36 were register studies, 4 randomized clinical trials, 4 COVID-19 articles, 4 reviews/ meta-analyses, 1 study protocol, 3 case reports/ technical notes, and 4 Guide-line articles and 10 Editorials/Annotations/Perspective. We published 2 Letters to the Editor.

## Submission and publication of manuscripts (Table)

593 manuscripts were submitted ( 674 in 2020, 495 in 2019, 573 in 2018, 864 in 2017, 885 in 2016).
$62 \%$ were clinical, $10 \%$ case reports, $8 \%$ experimental, and $3 \%$ reviews/meta-analyses, similar distribution since several years.
One third (206/593) of the manuscripts (ms) were submitted from NOF members, the fraction has been the same for several years.
Of the 125 published articles Sweden contributed with 34, Denmark 27, the Netherlands 17, Finland 14, Norway 9, Germany 4, South Korea 3, USA 5, China 3, and 1-2 each from 6 other countries.
24 published ms were from non-NOF members who accordingly paid APC. This number has been about the same since we started APC year 2018.

Please note that direct comparisons of the number of submitted manuscripts and published articles per country and year is not meaningful. There is an overlap between years; many of the ms submitted a specific year are published the next year.

## Handling of manuscripts and acceptance rate

Handling times have been about the same since almost 10 years: two thirds of ms (except those immediately rejected by in-house evaluation, < 1 week) have a first decision letter within 3 weeks, four fifths within 6 weeks.

For details of handling times see Editor's Report for year 2020 (all Reports are available on NOF's website: https://www.norf.org).
The time from acceptance to online publication on the publisher's website and in PubMed / PubMedCentral is within weeks.

The $20 \%$ acceptance rate (similar since several years) varies between countries (highest for the Nordic countries) but note that all manuscripts are evaluated by co-editors.

## Subscriptions

We had around 5,500 collective subscribers (NOF members) and 25 institutional subscriptions (mainly libraries) in 2021. Due to this low number we stopped the remaining paper prints to these subscribers, thus Acta is now digital only.

## Finances

The economy is in balance with a small surplus for 2021.

## Impact factor

Acta's impact factor 2021 increased to 3.9. For comparison over time and with other journals see Figure. Among the 86 journals classified as "Orthopedics" Acta ranked 19. The nr 1 was Journal of Physiotherapy, IF 11.


## Editor meetings, new co-editors

The Editors had 1 meeting, the first since 2019.
Rolf Önnefält resigns and was thanked for his 25 years in Acta. He is replaced by Cecilia Rogmark and Søren Övergaard. Philippe Wagner will share statistical editing with Jonas Ranstam.

## New Publisher

Our publisher Taylor \& Francis terminated our contract December 31, 2021 and proposed a new contract which, however, was not aceeptable why the NOF board and ExCom after research decided on a new publisher; Medical Journals Sweden (MJS https://medicaljournalssweden.se) active as from 2022.

Anders Rydholm 20220728

Manuscripts published

|  | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sweden | 40 | 53 | 46 | 53 | 55 | 51 | 39 | 48 | 60 | 17 | 21 | 21 | 21 | 29 | 22 | 26 | 26 | 34 |
| Denmark | 42 | 57 | 44 | 54 | 51 | 51 | 37 | 60 | 41 | 16 | 22 | 18 | 17 | 16 | 14 | 22 | 24 | 27 |
| Norway | 18 | 23 | 20 | 30 | 22 | 21 | 10 | 22 | 16 | 7 | 9 | 11 | 10 | 15 | 14 | 4 | 9 | 9 |
| Finland | 20 | 25 | 34 | 21 | 32 | 28 | 19 | 31 | 27 | 9 | 11 | 11 | 17 | 9 | 9 | 13 | 11 | 14 |
| Iceland |  | 1 |  | 1 |  | 2 |  | 1 |  |  | 1 |  |  | 1 |  |  |  |  |
| Estonia | 2 | 1 | 1 |  |  | 2 |  |  |  |  |  |  |  |  |  | 1 |  |  |
| Lithuania |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  | 1 |  |  |
| The Netherlands | 75 | 56 | 59 | 77 | 89 | 59 | 49 | 72 | 62 | 10 | 9 | 14 | 9 | 10 | 20 | 15 | 20 | 17 |
| Subtotal | 197 | 216 | 204 | 236 | 249 | 215 | 154 | 234 | 206 | 59 | 73 | 75 | 74 | 80 | 79 | 82 | 90 | 101 |
|  | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
| Australia | 20 | 12 | 11 | 14 | 10 | 7 | 8 | 10 | 5 | 2 | 1 | 4 | 1 | 4 | 1 | 1 | 1 | 2 |
| Austria | 19 | 26 | 20 | 12 |  | 8 | 11 | 14 | 8 | 1 |  | 2 | 2 |  |  | 1 |  | 2 |
| Belgium | 4 | 5 | 4 | 3 | 5 | 1 | 2 | 4 | 3 |  |  |  |  | 1 |  |  |  |  |
| Brazil |  |  | 8 | 8 | 6 | 3 | 1 | 3 | 2 |  |  |  |  | 1 |  |  |  |  |
| Canada | 13 | 10 | 8 | 6 | 7 | 9 | 3 | 2 | 2 |  | 2 | 2 |  |  | 1 | 1 |  |  |
| Chile |  |  |  |  | 3 |  |  | 1 | 3 |  |  |  |  | 1 |  |  | 1 |  |
| China | 68 | 80 | 94 | 127 | 77 | 115 | 118 | 102 | 141 | 2 | 1 | 1 | 1 |  | 1 | 1 | 2 | 3 |
| Colombia |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |
| Czech rep. |  |  |  |  |  |  |  | 2 | 2 |  |  |  |  |  |  |  |  |  |
| Egypt | 10 | 13 | 22 | 16 | 8 | 4 | 3 | 4 | 7 |  |  |  |  |  | 0 |  |  |  |
| France | 10 | 14 | 7 | 12 | 12 | 5 | 8 | 6 | 2 |  | 2 | 3 |  |  | 1 |  |  | 1 |
| Germany | 63 | 78 | 53 | 54 | 48 | 26 | 29 | 31 | 32 | 8 | 7 | 4 | 4 | 4 | 4 | 2 | 5 | 4 |
| Greece | 19 | 12 | 6 | 3 | 8 | 1 |  | 3 |  |  | 3 |  |  |  |  |  |  |  |
| India | 41 | 24 | 46 | 32 | 33 | 5 | 4 | 6 | 9 |  |  |  |  | 1 |  |  |  |  |



